Skip to main content

Table 2 Baseline characteristics

From: Effects of sitagliptin beyond glycemic control: focus on quality of life

  Enrolled subjects Evaluated subjects
  (n = 207) (n = 188)
Age (years) 66.5 ± 12.8 66.9 ± 12.6
Gender Male: 50% (n = 103), Male: 48% (n = 91),
Female: 50% (n = 104) Female: 52% (n = 97)
BMI 25.0 ± 4.4 kg/m2 25.0 ± 4.4 kg/m2
Waist circumference 89.4 ± 12.8 cm 89.0 ± 12.8 cm
Obesity (BMI > 25) 51% 50%
Duration of DM (years) 6.8 ± 6.5 6.9 ± 6.6
Smoking status Smoker: 24% Smoker: 23%
Past smoker: 13% Past smoker: 13%
Never: 63% Never: 63%
Alcohol consumption Yes: 30% Yes: 29%,
Complications HT: 67%, DL: 55%, HUA: 7%, HT: 65%, DL: 55%,
Arrhythmia: 5%, CKD 43% HUA: 6%, Arrhythmia: 5%,
  CKD 43%
Use of sitagliptin New: 35% New: 35%
Added: 45%, Changed: 20% Added 45%, Changed 20%
Combined drugs SU: 49%, BG: 20%, TZD: 28%, SU: 48%, BG: 22%,
Glinide: 2%, α-GI: 7% TZD: 28%, Glinide: 2%, α-GI: 7%
  1. BMI, Body mass index; DM, diabetes mellitus; HT, hypertension; DL, dyslipidemia; HUA, hyperuricemia; CKD, chronic kidney disease; SU, sulfonylurea; BG, biguanide; TZD, thiazolidinedione; α-GI, α-glucosidase inhibitor.